Gabather AB announces that the company has received approval from the Portuguese regulatory authority, INFARMED, to start the target-engagement study in healthy volunteers with the drug candidate GT-002. Screening and recruitment of individuals will start shortly. GT-002 is the most advanced selective GABAA receptor modulator with a unique mechanism of action that opens for the development of new and effective drugs against several neuropsychiatric diagnoses.

In the double-blind, placebo-controlled phase 1 study, healthy subjects will receive GT-002 in a so-called cross-over design study where the effect of GT-002 will be examined with electroencephalography (EEG) and magnetic resonance imaging (fMRI). The aim of the study is to investigate the effects of GT-002 on EEG signals and the location of the signals in the human brain.